Outcome of Pediatric Acute Lymphoblastic Leukemia: Sixty Years of Progress
Overview
Authors
Affiliations
Background: A retrospective analysis was performed to investigate the survival outcomes in pediatric acute lymphoblastic leukemia (ALL) based on time period. We hypothesized that improvement has been obtained with the time-dependent therapeutic era and rise in the gross domestic product (GDP) and Human Development Index (HDI).
Materials And Methods: Data from 710 children who were treated for ALL between 1958 and 2018 at a single pediatric center were analyzed for probability of 5-year overall survival (pOS), event-free survival (pEFS) and relapse risk (pRR). Time periods were defined by the treatment protocols used in seven consecutive therapeutic eras.
Results: Over the 60-year period analyzed, pOS increased from 1.2% to 90.7%, pEFS from 1.2% to 86.6%, and pRR decreased from 98.8% to 9.9% for patients treated in the past decade. Risk of mortality for patients who received chemotherapy and hematopoietic cell transplant was reduced to 9.9% in the recent era, however, no statistically significant survival difference was found between patients treated with stem cell transplant and those not.
Conclusion: The therapeutic era, related to improved GDP and HDI, was a statistically significant predictor of increased OS from ALL.
Simiakova M, Bielik V Front Pediatr. 2024; 12:1427185.
PMID: 39502562 PMC: 11534854. DOI: 10.3389/fped.2024.1427185.
Garcia-Gimenez A, Richardson S Front Oncol. 2023; 13:1150612.
PMID: 36959797 PMC: 10029760. DOI: 10.3389/fonc.2023.1150612.
Khan A, Zeb J, Farooq N, Farid N, Zeb R, Shoaib M Cureus. 2022; 14(5):e25403.
PMID: 35774667 PMC: 9239291. DOI: 10.7759/cureus.25403.
Styczynski J, Debski R, Czyzewski K, Gagola K, Marquardt E, Roszkowski K In Vivo. 2021; 35(6):3315-3320.
PMID: 34697163 PMC: 8627707. DOI: 10.21873/invivo.12627.
Qi H, Chi L, Wang X, Jin X, Wang W, Lan J Anal Cell Pathol (Amst). 2021; 2021:6692022.
PMID: 34211824 PMC: 8208884. DOI: 10.1155/2021/6692022.